A late-stage drug advancement company specific in oncology and endocrinology.

Aeterna Zentaris granted FDA orphan-drug designation for AEZS-108 in ovarian cancer Aeterna Zentaris Inc. , a late-stage drug advancement company specific in oncology and endocrinology, today announced that it provides received from the U.S. Food and Medication Administration , orphan-drug designation for AEZS-108, its doxorubicin targeted conjugate substance, for the treatment of ovarian cancer. AEZS-108 happens to be in a Phase 2 trial in advanced advanced and ovarian endometrial cancer in Europe. Juergen Engel, Ph. D., President and CEO of Aeterna Zentaris mentioned, ‘We are very happy with AEZS-108 gaining orphan-medication designation for ovarian cancers from the FDA since it would provide it with extra marketplace exclusivity protection.Dietary supplements in one Minute Miracle ABOUT A MINUTE Miracle initiated a voluntary recall of all plenty of its Miracle Diet 30 and Miracle Rock 48 dietary supplements due to the presence of undeclared items, making them unapproved medications. Miracle Diet plan 30 was discovered to include undeclared phenolphthalein, an ingredient used in an OTC laxative that was taken off the market amid issues of carcinogenicity, while Miracle Rock 48 was found to include undeclared thiosildenafil, an analogue of the FDA-approved male sexual enhancement drug sildenafil.